Landmark discoveries and advances in most cancers science present alternatives for improved scientific therapies. However to convey these therapies to the precise sufferers shortly and as safely as doable requires well-designed scientific trials.
On this Cell Press Digital Panel, we focus on scientific trial design for most cancers remedy. This panel brings collectively consultants within the area of scientific oncology: Lillian Siu from Princess Margaret Most cancers Heart, Carl June from the College of Pennsylvania’s Perelman Faculty of Drugs, and Patrick Ott from Dana-Farber Most cancers Institute. Moderated by Concord Turk of Most cancers Cell and Sara Hamilton of Cell Studies Drugs.
For extra digital panels and to discover the breadth of Cell Press most cancers analysis, be a part of us in celebrating Most cancers Analysis week
Click on the time stamp to leap to probably the most related query and dialogue.
01:42 What do you see as the main bottlenecks in scientific trials? And is there a solution to higher design trials to beat these hurdles?
12:06 May you touch upon any of the technical challenges related to these trials in the course of the scientific growth, applied sciences comparable to CRISPR-Cas9 and CAR T cell remedy?
19:46 What are among the particular issues for designing trials the place you might be testing a particular remedy in a number of completely different most cancers varieties on the identical time?
23:23 May you speak about among the key issues for designing trials for personalised vaccines?
45:08 How do you see information sharing affecting scientific trial design? Do you assume there are enhancements that may be made to the present information sharing strategies that would assist scientific trial design?
For a full transcript of this panel, go to